Ascendis Pharma Reports Third Quarter 2024 Financial Results
YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3– TransCon CNP ...
ESCO Reports Fourth Quarter and Fiscal 2024 Results
St. Louis, Nov. 14, 2024 (GLOBE NEWSWIRE) -- ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its operating results for the fourth quarter and fiscal year ended September 30, ...